C57BL/6 mice were implanted with murine glioma cell line GL261-luc2 and randomized into 8 treatment arms: (i) control, (ii) SRS(stereotactic radiosurgery), (iii) anti-PD-1 antibody, (iv) Tim-3 antibody, (v) anti-PD-1 + SRS, (vi) Tim-3 + SRS, (vii) anti-PD-1 + Tim-3, and (viii) anti-PD-1 + Tim-3 + SRS. Here, PDCD1 is linked to central nervous system cancer.